Q-omics provides the consensus-scored HOXB1 profile across patient tissues and cancer cell-line models. HOXB1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, HOXB1 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, HOXB1 protein abundance shows 14,727 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where HOXB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HOXB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HOXB1 survival associations across molecular data types. HOXB1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HOXB1 RNA expression–survival associations across cancer types. High HOXB1 expression shows unfavorable associations in SKCM, OV, ACC and COAD, but favorable associations in LUSC and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for HOXB1 RNA expression.
This table summarizes HOXB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for HOXB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HOXB1 shows lower tumor expression in KIRC and KIRP and higher tumor expression in BRCA, LUSC and PAAD. The KIRC box plot shows higher HOXB1 RNA expression in normal versus tumor tissue (log2 FC = −0.410, t-test p < 0.001).
This table shows molecular features associated with HOXB1 in patient tissues and cancer cell lines. In patient samples, HOXB1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, HOXB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
